Physician profile
Muhammad Azhar
NPI 1316155534
$2,178.14
in general payments reported to CMS, 2019-2025
21 companies · $156 in 2025
The $156 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $421 · 2020: $303 · 2021: $539 · 2022: $439 · 2023: $120 · 2024: $200 · 2025: $156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $477.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $476.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $326.53 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $245.50 | 2019-2021 | |
| Lundbeck LLC | $219.35 | 2019-2025 | Rexulti |
| Abbvie INC. | $217.24 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $196.04 | 2022-2025 | Ingrezza |
| Neos Therapeutics, LP | $191.81 | 2019-2023 | Adzenys Xr-Odt |
| Janssen Pharmaceuticals, INC | $130.80 | 2019-2024 | Spravato |
| Ironshore Pharmaceuticals INC. | $110.61 | 2020-2024 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $100.03 | 2021-2025 | Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $96.48 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $80.32 | 2019-2025 | Rexulti |
| Idorsia Pharmaceuticals US INC | $54.43 | 2022-2024 | Quviviq |
| Alkermes, INC. | $47.66 | 2023 | Aristada, Lybalvi |
| Corium, LLC | $36.63 | 2022 | |
| Adlon Therapeutics L.P. | $32.25 | 2020-2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $23.90 | 2025 | Cobenfy |
| Rhodes Pharmaceuticals L.P. | $15.02 | 2019 | |
| Collegium Pharmaceutical, INC. | $14.64 | 2025 | Jornay Pm |
| Arbor Pharmaceuticals, INC. | $13.81 | 2019 | |
| Vertical Pharmaceuticals, LLC | $13.51 | 2019 | |
| Eisai INC. | $11.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Azhar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.